Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    14-September-2000      
Issue 154 Next Update - 14:00 UTC 08:00 EST    15-September-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya Today In Vidyya sm

Newsletter Summary For 14-September-2000:

In today's news, several recent studies have suggested that the use of AZT to prevent the spread of HIV from mother to child may result in cardiac abnormalities in children. Now new data from an NHLBI pediatric AIDS study provide reassuring evidence that AZT is not associated with any significant negative clinical effects on the heart. These data show no significant differences in cardiac function between children exposed to AZT and those not exposed, regardless of their HIV status.

Researchers at the National Institutes of Health (NIH) report that advanced kidney cancer, a disease notoriously resistant to therapy and usually fatal, can be completely or partially reversed in some patients with the use of blood stem cell transplants from a healthy sibling donor. Using this investigational approach, substantial and occasionally complete regression of widespread tumors was observed in the majority of 19 patients with treatment-resistant metastatic renal cell carcinoma who were treated at the National Heart, Lung, and Blood Institute (NHLBI) Stem Cell Transplant unit.

In drug news, Wyeth-Ayerst Laboratories, of Philadelphia, Pa, the maker of The Norplant System, a 5-year contraceptive implant, is advising doctors to inform patients who had the product inserted since October 20, 1999 to use an additional (backup) method of contraception. The company is issuing an update of a letter sent on August 10, 2000 that advised health care professionals to discontinue inserting kits from specific lots.

In FDA news, a new treatment for gallstone disease without an incision has received Food and Drug Administration (FDA) approval. The method should provide an attractive, less expensive option for the 25 million Americans who suffer from gallstones, who refuse surgery or who are not good candidates for surgery, or who's calculi are identified in early stages.

And finally, the CDC invites comments on the comprehensiveness, clarity, coherence and viability of a draft of its five-year strategic plan to prevent the spread of HIV. The Centers are especially interested in learning about any gaps you perceive. The plan is available in today's Vidyya, on CDCís website and through the CDC National Prevention Information Network by calling 1-800-458-5231. The public comment period runs until 23 October 2000.

The articles in today's Vidyya are:

As always, we hope you enjoy the issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.